Phase Ib Study of Gemcitabine Plus Cisplatin or Carboplatin Plus Dovitinib in Patients With Advanced Solid Tumors
Status:
Terminated
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
This is a phase Ib dose escalation study of dovitinib given in combination with either
gemcitabine plus cisplatin or carboplatin in patients with advanced solid tumors. Patients
with advanced solid tumors, for whom treatment with gemcitabine plus cisplatin or carboplatin
would otherwise be warranted, will be enrolled. The dose of dovitinib will be escalated in
successive cohorts using standard "3+3" dose escalation rules. Patients will continue
treatment, in the absence of prohibitive toxicity, until disease progression. The study will
define the recommended phase II dose of these combination regimens.